#	Pagina
attuale pagina	/open-h2020/projects/219838/index.html
-1	/open-h2020/projects/193562/index.html
-2	/open-h2020/projects/194697/index.html
-3	/open-h2020/projects/215574/index.html
-4	/open-h2020/per-topic/microparticles/list/index.html
-5	/open-h2020/projects/220929/index.html
-6	/open-h2020/projects/208284/index.html
-7	/open-h2020/projects/219470/index.html
-8	/open-h2020/projects/215062/index.html
-9	/open-h2020/per-topic/multiscriptal/list/index.html
-10	/open-h2020/projects/207590/index.html

Opendata, web and dolomites

UPGRADE SIGNED

Unlocking Precision Gene Therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

UPGRADE project word cloud

Explore the words cloud of the UPGRADE project. It provides you a very rough idea of what is the project "UPGRADE" about.

components vectors hematopoiesis models poor definitive amp otherwise prototypes tissue disruptive transfer upgrade treatments strategies specificity transgene technologies insertional opening groups liver mutagenesis storage immune seven generate cure evasion hypercholesterolemia conventional skeletal correction sequence versatile complementing validated durability cell stringently wasting cellular incurable portable profile limitations hurdles shown reached silence broaden limited tools overcome risk therapy gene genome indications heart entering precision viral combine medicinal vehicles activate paradigmatic realize full off remarkable insertion unmet clinical disorders editing retina blood epigenome treatment basis amps efficacy market pathogenesis disease precise diseases patient site tissues scope solutions recode radical tackling medical efficiency safety muscle

Project "UPGRADE" data sheet

The following table provides information about the project.

Coordinator	FONDAZIONE TELETHON Organization address address: VIA VARESE 16/B city: ROMA postcode: 185 website: www.telethon.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	14˙996˙955 €
EC max contribution	14˙995˙830 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2023-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FONDAZIONE TELETHON FONDAZIONE TELETHON Organization address address: VIA VARESE 16/B city: ROMA postcode: 185 website: www.telethon.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	coordinator	5˙027˙968.00
2	UNIVERSIDAD POMPEU FABRA UNIVERSIDAD POMPEU FABRA Organization address address: PLACA DE LA MERCE, 10-12 city: BARCELONA postcode: 8002 website: www.upf.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	2˙767˙377.00
3	UNIVERSITA DEGLI STUDI DI TRENTO UNIVERSITA DEGLI STUDI DI TRENTO Organization address address: VIA CALEPINA 14 city: TRENTO postcode: 38122 website: www.unitn.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (TRENTO)	participant	1˙333˙798.00
4	VRIJE UNIVERSITEIT BRUSSEL VRIJE UNIVERSITEIT BRUSSEL Organization address address: PLEINLAAN 2 city: BRUSSEL postcode: 1050 website: www.vub.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUSSEL)	participant	1˙328˙412.00
5	THE GENERAL HOSPITAL CORPORATION THE GENERAL HOSPITAL CORPORATION Organization address address: FRUIT STREET 55 city: BOSTON MA postcode: 2114 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (BOSTON MA)	participant	1˙217˙710.00
6	UNIVERSITE DE NANTES UNIVERSITE DE NANTES Organization address address: QUAI DE TOURVILLE 1 city: NANTES CEDEX 1 postcode: 44035 website: www.univ-nantes.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (NANTES CEDEX 1)	participant	1˙107˙500.00
7	TECHNISCHE UNIVERSITAET DRESDEN TECHNISCHE UNIVERSITAET DRESDEN Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 website: http://www.tu-dresden.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	1˙107˙000.00
8	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Organization address address: GESCHWISTER SCHOLL PLATZ 1 city: MUENCHEN postcode: 80539 website: www.uni-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	1˙106˙062.00

Map

Project objective

Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene therapy products have reached the market and many more are entering clinical testing for selected indications. Moreover, emerging technologies for targeted gene editing are complementing the scope of conventional gene transfer, opening the way to precise gene correction and making possible to silence, activate or recode any sequence of interest in the genome. However, in order to realize the full potential of these strategies and broaden application of gene therapy, the field has to solve several major hurdles, including: risk of insertional mutagenesis by gene transfer vectors, limited efficiency and durability of some gene correction strategies, off target effects of editing tools, poor tissue targeting and immune response to editing components and delivery vehicles. UPGRADE will offer radical new solutions to overcome these hurdles. We will exploit and further develop disruptive new technologies for precision gene and epigenome editing and for site-specific transgene insertion, and stringently characterize their specificity and cellular responses. We will combine these improved technologies with advanced viral and non-viral vectors enabling cell/tissue targeting and immune evasion, to generate prototypes of advanced medicinal products (AMP). The safety and efficacy profile of each AMP will be stringently validated in tissues (hematopoiesis, heart and skeletal muscle, liver, retina) and disease models (muscle wasting, storage and blood disorders, hypercholesterolemia) paradigmatic for unmet medical need and potential long-term cure, if the limitations of current gene therapy strategies are overcome. These AMPs represent versatile products portable to the treatment of several other diseases because of related pathogenesis or correction strategies, thus providing the basis for tackling diseases affecting large patient groups.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "UPGRADE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "UPGRADE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More